What is William Blair’s Estimate for Nkarta Q1 Earnings?

Nkarta, Inc. (NASDAQ:NKTX) – Analysts at William Blair cut their Q1 2025 earnings per share estimates for Nkarta in a research note issued on Thursday, March 27th. William Blair analyst S. Corwin now expects that the company will post earnings per share of ($0.44) for the quarter, down from their prior estimate of ($0.42). The consensus estimate for Nkarta’s current full-year earnings is ($1.70) per share. William Blair also issued estimates for Nkarta’s Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.46) EPS, Q4 2025 earnings at ($0.46) EPS and FY2025 earnings at ($1.81) EPS.

Other research analysts have also issued research reports about the stock. HC Wainwright restated a “buy” rating and set a $18.00 price target on shares of Nkarta in a research note on Thursday, March 27th. Stifel Nicolaus decreased their price objective on shares of Nkarta from $15.00 to $14.00 and set a “buy” rating for the company in a report on Thursday, March 27th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 target price on shares of Nkarta in a research report on Thursday, March 27th. Six analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $14.86.

Nkarta Stock Performance

NASDAQ:NKTX opened at $1.85 on Monday. The company has a market capitalization of $130.92 million, a P/E ratio of -0.98 and a beta of 0.90. The stock’s 50 day moving average price is $1.97 and its 200 day moving average price is $2.76. Nkarta has a 52 week low of $1.31 and a 52 week high of $10.48.

Nkarta (NASDAQ:NKTX) last posted its quarterly earnings results on Wednesday, March 26th. The company reported ($0.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.06.

Insider Buying and Selling

In other news, CEO Paul J. Hastings sold 17,378 shares of the firm’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $2.20, for a total value of $38,231.60. Following the sale, the chief executive officer now owns 319,859 shares in the company, valued at approximately $703,689.80. This trade represents a 5.15 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 8.70% of the stock is owned by insiders.

Institutional Trading of Nkarta

Several hedge funds and other institutional investors have recently bought and sold shares of NKTX. Erste Asset Management GmbH acquired a new position in shares of Nkarta during the third quarter valued at about $33,000. Invesco Ltd. bought a new position in Nkarta during the fourth quarter valued at about $30,000. Sequoia Financial Advisors LLC acquired a new position in Nkarta in the 4th quarter valued at approximately $31,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Nkarta during the 4th quarter worth approximately $37,000. Finally, Intech Investment Management LLC acquired a new stake in shares of Nkarta during the 3rd quarter worth approximately $74,000. 80.54% of the stock is currently owned by institutional investors and hedge funds.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.